Australia's Lumos Diagnostics gains on advancing respiratory test sales

Lumos Diagnostics Holdings

14/05/2025 03:31

** Lumos Diagnostics LDX.AX rises 3.9% to A$0.027; marks biggest intraday percentage gain since May 7

** Medical equipment supplier says it received and shipped $126,000 purchase order for FebriDx from iMedical, Inc.

** Adds order largest single purchase order since the test's launch; signals rise in U.S. customer adoption and continued market acceptance of FebriDx

** FebriDx is a rapid point-of-care respiratory test, which, according to Lumos, delivers results in around 10 minutes from a fingerstick blood sample

** LDX falls 25.7% this year, as of last close

 (Reporting by Sherin Sunny in Bengaluru)

 ((Sherin.Sunny@thomsonreuters.com;))